TRANSCATHETER CARDIOVASCULAR THERAPEUTICS ASIA PACIFIC





## **Usefulness of OCT in Preclinical Study**

### Kim, Jung-Sun, M.D. Ph D

#### Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine





# I have nothing disclosure to this presentation





## Development of Animal Model

## New device evaluation





## Development of Animal Model

## New device evaluation



## **Vulnerable Plaque**

**Histological Aspect** 



Vancraeynest D, et al. J Am Coll Cardiol 2011;57:1961-79



### Why We Need a Animal Model with Vulnerable Plaque

- TCFA appear to be the most common type of VP in autopsy study.
- But, the mechanism of plaque rupture and subsequent occlusive thrombus formation is still unclear.
- The need to identify and characterize vulnerable atherosclerotic lesions in human has led to the development of various animal model of plaque vulnerability.



#### Vascular lesion harvested from the proximal left anterior descending artery 10 weeks after adventitial liposome delivery



Granada JF et al. Arterioscler Thromb Vasc Biol 2007;27:387-393





Plaque harvested from the LAD in a pig at 10 weeks of follow-up. A, Movat pentachrome section (2) showing a fibrolipidic plaque with no evidence of calcification. B, Corresponding IVUS-VH image acquired in vivo showing significant amount of necrotic core and calcification.

The sensitivity of IVUS-VH for the detection of fibrous, fibro-fatty, and necrotic core tissue was 76.1%, 46%, and 41.1%.

This model is rich in smooth muscle cells/proteoglycans and the lesions lack a necrotic core, calcification, and collagen (type I). Therefore, this model might be more indicative of a restenosis model.

Severance Cardiovascular Hospital



## **Clinical imaging modalities**



- $\succ$  OCT provides images with resolutions of 10 15 µm and depths of 2-3 mm
- > Imaging resolution is 10 times better than ultrasound



## **Swine Model**

RCA

## LCA





### **Vulnerable Plaque Model in Swine Model**



#### **Post-Injection**

#### 2 weeks follow-up



### **Vulnerable Plaque Model in Swine Model**

#### **Preliminary Data**

Inject with HMGB1 (RAGE ligand) + cholesterol esters using Mecator catheter



#### 2 weeks follow-up



#### Intra-aortic OCT in a mouse apolipoprotein E–/– model.



Tahara S et al. Arterioscler Thromb Vasc Biol 2012;32:1150-1157



## Macrophage accumulation detected by intra-aortic OCT and immunohistochemistry in apolipoprotein E (ApoE)–/– mice.



Tahara S et al. Arterioscler Thromb Vasc Biol 2012;32:1150-1157



#### In vivo optical coherence tomography of experimental thrombosis in a rabbit carotid model

Figure 2 Comparative analysis of the histomorphometric and OCT features of carotid artery thrombus presence or absence of thrombus. Correlation between OCT images obtained in vivo and later histological examination of animal model red thrombi. A, B and C show OCT images of the right common carotid artery cross-sections, with each showing a signal-rich mass protruding into the lumen. The corresponding histological sections, D, E and F, confirm the thrombus within the lumen of the common carotid artery at these levels. OCT images of red thrombi are characterised as high-backscattering protrusions with signal-free shadowing (arrows). Red thrombus, which is a cellrich structure and consists mainly of red blood cells, causes scatter and attenuation of OCT signal intensity from the inner surface of the thrombus to the vessel wall. OCT was able to determine the presence or absence of a thrombus in all arterial segments.



Meng L, et al. Heart 2007;94:777-780



### **Techniques for Imaging the Unstable Plaque.**



Matter C M et al. Eur Heart J 2009;30:2566-2574





## Development of Animal Model

## New device evaluation



## **OCT vs. IVUS**





#### The degree of angiographic LL in DESs < 0.4 mm,

#### The resolution threshold of angiography : around 0.5 mm

## Evaluate the correlation of angiographic late loss (LL) with the degree of in-stent neointimal proliferation assessed by optical coherence tomography (OCT) and histology









Kim JS, Granada JF, et al. J Am Coll Cardiol Img 2011;4:1002-10





Kim JS, Granada JF, et al. J Am Coll Cardiol Img 2011;4:1002-10





Severance Cardiovascular Hospital

٢

#### Comparison of neointimal formation on struts crossing the sidebranch



Cypher (SES)

Taxus (PES)

#### **Endeavor (ZES)**

Her AY, Hong MK, et al. Am J Cardiol 2010;105:1565-9







ΟCΤ

Histology

2 struts are covered with SMC-rich neointima, 1 strut covered with proteoglycan- rich, 1 strut covered with proteoglycan-rich but partially uncovered (bare strut)

Interpreted by CVPath



## **Evaluation of Flushing Solution**



**100 % Contrast 50 % Contrast + Dextran** 

#### Dextran

Severance Cardiovascular Hospital



### **Dextrose Solution**

Dextran or Contrast could cause a renal impairment.

### 10 % DW or 20 % DW

-> Not clear image and induce frequent PVC's and ST segment change.

Cannot apply in clinical practice because of safety issue.



### **Bioabsorbable everolimus eluting stent (BVS)**





**OCT (Stent strut thickness 150um)** 



CT delineates easily the contours of the stented vessel because the stent structures are not radio-opaque

Serruys PW, et al. Lancet 2009;373:897-910

Severance Cardiovascular Hospital



### **Preclinical porcine studies**



Onuma Y, et al. Circulation 2010;122:2280-300



Von Kossa Stain Mineralization seen around preexisting BVS struts. It is typically seen on most DES struts.



Alcian Blue Stain Proteoglycan encompassing and replacing the pre-existing BVS stent struts

Severance Cardiovascular Hospital





Different characteristics of stent strut coverage at different time points after stent implantation, fibrin- vs. neointima-covered stent struts

Different characteristics of stent strut coverage at different time points after stent implantation, i.e. fibrin- vs. neointimacovered stent struts. (A) Fibrin at Day 3 in SEM and OFDI, where a low intensity of stent strut coverage can be seen (A''''); (B) neointima at Day 10 in SEM and OFDI, where stent strut coverage with higher intensity when compared with fibrin can be observed; (C) neointima at Day 28 in SEM and OFDI, where a high intensity of stent strut coverage is present (is, intensity of strut; it, intensity of tissue).

Templin C et al. Eur Heart J 2010



## **Change of Neotintimal Tissue after Stenting**

Delayed vascular healing after DES implantation is suggested as a strong predictor among several factors. In addition, recent studies demonstrated that development of neoatherosclerosis within neointimal tissues could be another cause of stent thrombosis due to neointimal rupture

Evaluate different OCT morphological characteristics with different in-stent neointimal tissue types analyzed by histology



### Serial follow-up OCT finding



Kim JS, Hong MK, et al. J Am Coll Cardiol Img 2012 in press

Severance Cardiovascular Hospital



## **Serial Stent Evaluation**



### Waiting for 6 months follow-up

#### 3 months weeks



## **Serial Stent Evaluation**



#### **1** Month after stent implantation

#### **3** Months after stent implantation

Severance Cardiovascular Hospital





#### Representative images of OCT and histologic sections.

(A) Homogeneous neointimal pattern in OCT has a collagen rich neointima (bluish color) (B) heterogeneous neointimal pattern shows lots of loose connective tissue (grey color) and fibrin (pink color) (C) layered neointimal pattern shows thick neointima, external elastic laminal rupture and peristrut inflammation (D) neovascularization is shown in the middle of neointima. **Kim JS, Granada JF, et al. TCT 2011** 





### Histological evaluation of OCT neointimal pattern.

\*: p<0.05 between homogeneous and heterogeneous group, <sup>†</sup>: p<0.05 between homogeneous and layered group, <sup>‡</sup>: p<0.05 between heterogeneous and layered group **Kim JS, Granada JF, et al. TCT 2011** 



## **Advantage and Pitfalls**

-Intravascular OCT is a high-resolution intravascular imaging modality that can be used to evaluate the surface vascular structure.

- Limited penetration and scan area – need a hybrid modality.





-Intravascular OCT is a high-resolution intravascular imaging modality that can be used to evaluate the surface vascular structure and thin neointimal tissue *in Pre-clinical study*.

-It is useful to evaluate the adequate animal model.

- It is also valuable to assess the efficacy and safety evaluation of newly developed intravascular devices.



### **Thanks for Your Attentions**



## **Cardiovascular Product Evaluation Center**



**Conference** Room



Angio Room

**Control Room** 





Rabbit Cage

Severance Cardiovascular Hospital



JACC: CARDIOVASCULAR IMAGING © 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION PUBLISHED BY ELSEVIER INC.

### Ex Vivo Assessment of Vascular Response to Coronary Stents by Optical Frequency Domain Imaging

Masataka Nakano, MD,\* Marc Vorpahl, MD,\* Fumiyuki Otsuka, MD,\* Masanori Taniwaki, MD,† Saami K. Yazdani, PHD,\* Aloke V. Finn, MD,‡ Elena R. Ladich, MD,\* Frank D. Kolodgie, PHD,\* Renu Virmani, MD\* *Gaithersburg, Maryland; Tokyo, Japan; and Atlanta, Georgia* 

**METHODS** Fourteen human stented coronary segments with implant duration  $\geq$ 1 month from 10 hearts acquired at autopsy were interrogated ex vivo by OFDI and intravascular ultrasound (IVUS). Comparison with histology was assessed in 134 pairs of images where the endpoints were to investigate: 1) accuracy of morphological measurements; 2) detection of uncovered struts; and 3) characterization of neointima.







## Well Apposed Stent



## **Malapposed Stent**



### Atheroma OFDI-NIRF In Vivo Imaging



#### Slide Courtesy of Dr. JW Kim



The **recommendation** of **U.S. Food and Drug Administration** for pre-clinical stent data.

- Several time points should be used for the evaluation of DES performance, **the first at 28 days** to observe for neointimal hyperplasia, and at least 1 later time point to examine long-term effects.

- The **later time point (3 or 6 months)** depends on when "healing" and drug release are both complete.

Suzuki, Y. et al. J Am Coll Cardiol Intv 2009;2:373-383

